Leap Therapeutics Inc - Understand $lptx stock

$LPTX Market Cap: $110.2 Million

Research Board Inbox Deep Research Not Interested Shortlisted

Financial Snapshot

Revenue

$0.00

TTM

Gross Margin

Net Earnings

-$60.11M

TTM

Current Assets

$79.59M

Q2 2024

Current Liabilities

$15.60M

Q2 2024

Current Ratio

510.21%

Q2 2024

Total Assets

$81.43M

Q2 2024

Total Liabilities

$15.64M

Q2 2024

Book Value

$65.79M

Q2 2024

Cash

$78.48M

Q2 2024

P/E

-1.833

Sep 18, 2024 EST

Free Cash Flow

Revenues

Revenue YoY Change

Revenues

Concept	2023	2022	2021	2020	2019	2018	2017	2016	2015	2014
Revenue	$0.00	$0.00	$1.500M	$1.500M	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00
YoY Change		-100.0%	0.0%

Expenses

Cost Of Revenues

Gross Profit

Gross Profit Margin

Gross Profit

Concept	2023	2022	2021	2020	2019	2018	2017	2016	2015	2014
Revenue	$0.00	$0.00	$1.500M	$1.500M	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00
Cost Of Revenue
Gross Profit
Gross Profit Margin

Selling, General & Admin Expense

Research & Development

Depreciation, Depletion & Amortization

SGA Expense to Gross Profit Ratio

R&D To Gross Profit Ratio

DDA To Gross Profit Ratio

Operating Expenses Total

Operating Profits/Loss

Operational Expenses

Concept	2023	2022	2021	2020	2019	2018	2017	2016	2015	2014
Selling, General & Admin	$13.81M	$11.80M	$10.77M	$9.620M	$9.090M	$8.920M	$9.850M	$4.230M	$1.510M	$920.0K
YoY Change	17.03%	9.59%	11.91%	5.83%	1.91%	-9.44%	132.86%	180.13%	64.13%
% of Gross Profit
Research & Development	$73.23M	$44.97M	$32.16M	$20.42M	$24.37M	$21.83M	$22.50M	$23.29M	$10.41M	$6.710M
YoY Change	62.87%	39.82%	57.47%	-16.2%	11.64%	-2.98%	-3.39%	123.73%	55.14%
% of Gross Profit
Depreciation & Amortization	$15.00K	$16.00K	$29.00K	$34.00K	$50.00K	$50.00K	$50.00K	$30.00K
YoY Change	-6.25%	-44.83%	-14.71%	-32.0%	0.0%	0.0%	66.67%
% of Gross Profit
Operating Expenses	$87.04M	$56.76M	$42.93M	$30.04M	$33.45M	$30.75M	$32.35M	$27.52M	$11.92M	$7.630M
YoY Change	53.34%	32.23%	42.9%	-10.2%	8.78%	-4.95%	17.55%	130.87%	56.23%
Operating Profit	-$87.04M	-$56.76M	-$41.43M	-$28.54M
YoY Change	53.34%	37.02%	45.16%

Interest Expenses

Interest Expenses To Operating Income %

Other Expense/Income

Interest & Other Expense/Income

Concept	2023	2022	2021	2020	2019	2018	2017	2016	2015	2014
Interest Expense	$4.026M	$54.00K	$41.00K	$39.00K	$420.0K	$6.880M	$810.0K	-$1.230M	-$130.0K	-$70.00K
YoY Change	7355.56%	31.71%	5.13%	-90.71%	-93.9%	749.38%	-165.85%	846.15%	85.71%
% of Operating Profit
Other Income/Expense, Net	$1.601M	$2.051M	$1.226M	$230.0K	$130.0K	$760.0K	$1.660M	$3.120M
YoY Change	-21.94%	67.29%	433.04%	76.92%	-82.89%	-54.22%	-46.79%

Income/Loss

Pretax Income

Income Tax

Net Profits/Loss

Pretax Income YoY Change

Income Tax Rate

Net Profits/Loss YoY Change

Basic EPS

Net Income To Revenue Ratio

Pretax & Net Income

Concept	2023	2022	2021	2020	2019	2018	2017	2016	2015	2014
Pretax Income	-$81.41M	-$54.45M	-$40.61M	-$27.52M	-$32.90M	-$23.12M	-$29.88M	-$25.63M	-$12.05M	-$7.710M
YoY Change	49.52%	34.07%	47.59%	-16.36%	42.3%	-22.62%	16.58%	112.7%	56.29%
Income Tax	$0.00	$147.0K	-$24.00K	-$2.000K	$0.00	$20.00K	$11.14M	$0.00	$0.00	$0.00
% Of Pretax Income
Net Earnings	-$81.41M	-$54.60M	-$40.59M	-$27.51M	-$32.90M	-$23.14M	-$29.73M	-$25.63M	-$12.05M	-$7.710M
YoY Change	49.12%	34.52%	47.51%	-16.37%	42.18%	-22.17%	16.0%	112.7%	56.29%
Net Earnings / Revenue			-2705.8%	-1834.27%
Basic Earnings Per Share	-$3.98	-$0.48	-$0.47	-$0.63
Diluted Earnings Per Share	-$3.98	-$0.48	-$0.47	-$0.63	-$1.457M	-$1.636M	-$3.246M	-$2.727M	-$1.282M	-$820.2K

Assets & Liabilities

Cash & Short-Term Investments

Cash & Equivalents

Cash To Operating Expenses Ratio

Inventory

Receivables

Total Short-Term Assets

Property, Plant And Equipment

Long-Term Investments

Total Long-Term Assets

Total Assets

Net Income To Total Assets Percentage

Accounts Payable

Short-Term Debt

Long Term Debt Due

Total Short-Term Liabilities

Long-Term Debt

Other Long-Term Liabilities

Total Long-Term Liabilities

Total Liabilities

Short-Term To Long-Term Debt Ratio

Short-Term Assets To Debt Ratio

Long-Term Debt To Net Income Ratio

Assets & Liabilities

Concept	2023	2022	2021	2020	2019	2018	2017	2016	2015	2014
Cash & Short-Term Investments	$70.64M	$65.50M	$114.9M	$52.07M	$3.890M	$16.28M	$25.74M	$790.0K	$410.0K	$240.0K
YoY Change	7.85%	-43.0%	120.7%	1238.56%	-76.11%	-36.75%	3158.23%	92.68%	70.83%
Cash & Equivalents	$70.64M	$65.50M	$114.9M	$52.07M	$3.890M	$16.28M	$25.74M	$790.0K	$410.0K	$240.0K
Short-Term Investments
Other Short-Term Assets	$183.0K	$351.0K	$769.0K	$130.0K	$170.0K	$200.0K	$180.0K	$180.0K	$90.00K	$70.00K
YoY Change	-47.86%	-54.36%	491.54%	-23.53%	-15.0%	11.11%	0.0%	100.0%	28.57%
Inventory
Prepaid Expenses
Receivables
Other Receivables
Total Short-Term Assets	$71.60M	$67.95M	$116.9M	$52.27M	$4.240M	$17.32M	$27.66M	$4.030M	$490.0K	$310.0K
YoY Change	5.37%	-41.86%	123.6%	1132.78%	-75.52%	-37.38%	586.35%	722.45%	58.06%
Property, Plant & Equipment	$262.0K	$689.0K	$495.0K	$590.0K	$1.150M	$90.00K	$140.0K	$120.0K
YoY Change	-61.97%	39.19%	-16.1%	-48.7%	1177.78%	-35.71%	16.67%
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments
YoY Change
Other Assets	$966.0K	$1.714M	$542.0K	$1.500M	$2.060M	$1.670M	$1.270M	$2.310M	$770.0K	$830.0K
YoY Change	-43.64%	216.24%	-63.87%	-27.18%	23.35%	31.5%	-45.02%	200.0%	-7.23%
Total Long-Term Assets	$1.228M	$2.403M	$1.037M	$2.100M	$3.210M	$1.750M	$1.400M	$2.430M	$770.0K	$830.0K
YoY Change	-48.9%	131.73%	-50.62%	-34.58%	83.43%	25.0%	-42.39%	215.58%	-7.23%
Total Assets	$72.83M	$70.35M	$117.9M	$54.37M	$7.450M	$19.07M	$29.06M	$6.460M	$1.260M	$1.140M
YoY Change
Accounts Payable	$6.465M	$5.657M	$4.189M	$2.720M	$4.570M	$3.580M	$2.620M	$3.230M	$2.050M	$1.010M
YoY Change	14.28%	35.04%	54.01%	-40.48%	27.65%	36.64%	-18.89%	57.56%	102.97%
Accrued Expenses	$6.219M	$5.568M	$5.798M	$3.160M	$3.920M	$2.870M	$3.460M	$2.660M	$480.0K	$510.0K
YoY Change	11.69%	-3.97%	83.48%	-19.39%	36.59%	-17.05%	30.08%	454.17%	-5.88%
Deferred Revenue
YoY Change
Short-Term Debt	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$30.27M	$3.140M	$3.140M
YoY Change							-100.0%	864.01%	0.0%
Long-Term Debt Due
YoY Change
Total Short-Term Liabilities	$12.68M	$11.23M	$9.987M	$7.370M	$8.490M	$6.450M	$6.080M	$36.16M	$5.670M	$4.670M
YoY Change	13.0%	12.4%	35.51%	-13.19%	31.63%	6.09%	-83.19%	537.74%	21.41%
Long-Term Debt	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00
YoY Change
Other Long-Term Liabilities	$0.00	$262.0K	$37.00K	$350.0K	$710.0K	$3.450M	$11.86M
YoY Change	-100.0%	608.11%	-89.43%	-50.7%	-79.42%	-70.91%
Total Long-Term Liabilities	$0.00	$262.0K	$37.00K	$350.0K	$710.0K	$3.450M	$11.86M	$0.00	$0.00	$0.00
YoY Change	-100.0%	608.11%	-89.43%	-50.7%	-79.42%	-70.91%
Total Liabilities	$12.68M	$11.49M	$10.02M	$7.720M	$9.200M	$9.900M	$17.95M	$36.16M	$5.670M	$4.670M
YoY Change	10.42%	14.59%	29.84%	-16.09%	-7.07%	-44.85%	-50.36%	537.74%	21.41%

Ownership

Basic Shares Outstanding

Diluted Shares Outstanding

Preferred Stock

Treasury Stock Shares

Stock Issuance & Repurchase

Ownership Data

Concept	2023	2022	2021	2020	2019	2018	2017
Basic Shares Outstanding	20.45M	113.2M	85.83M	59.33M	22.58M	14.14M	9.162M
Diluted Shares Outstanding	20.45M	113.2M	85.83M	59.33M
Preferred Stock
Treasury Stock Shares

Return On Shareholders' Equity

Book Value

Free Cash Flow

Free Cash Flow YoY

Dividends

Stock Price

Market Cap: $110.2 Million

About Leap Therapeutics Inc

Leap Therapeutics, Inc. is a clinical stage biopharmaceutical company, which engages in developing novel therapies designed to treat patients with cancer. The company is headquartered in Cambridge, Massachusetts and currently employs 54 full-time employees. The company went IPO on 2017-01-24. The firm is focused on developing targeted and immuno-oncology therapeutics. Its advanced clinical candidate, DKN-01, is a humanized monoclonal antibody targeting the Dickkopf-related protein 1 (DKK1) protein. DKK1 is also a modulator of CKAP4/PI3K/AKT signaling. DKN-01 is being developed in patients with esophagogastric, gynecologic, and colorectal cancers. Its second clinical-stage program is FL-301, a humanized monoclonal antibody targeting Claudin18.2, being developed in patients with gastric and pancreatic cancer. The company also has two preclinical antibody programs, FL-302 and FL-501. FL-302 is a Claudin18.2/CD137 (also known as 4-1BB) bispecific antibody that is in preclinical development. FL-501 is a monoclonal antibody in preclinical development that targets growth and differentiation factor 15 (GDF15), which is a cytokine that is produced at elevated levels in response to various stresses.

Industry: Pharmaceutical Preparations Peers: Adverum Biotechnologies Inc Bioxytran Inc Axcella Health Inc. Checkpoint Therapeutics Inc Eliem Therapeutics Inc HCW Biologics Inc Q32 Bio Inc Longeveron Inc SPECTRUM PHARMACEUTICALS INC